10-Q: Electromedical Technologies Reports Q1 2024 Results, Navigating Financial Challenges Amid Product Transition

Electromedical Technologies reports a decrease in net sales for Q1 2024, alongside an increased net loss, as it transitions to a new product line and addresses ongoing financial uncertainties.

Summary

• Electromedical Technologies, Inc. reported net sales of $290,244 for the three months ended March 31, 2024, a decrease of 23% compared to $378,646 for the same period in 2023.
• The company's net loss increased to $836,274 for Q1 2024, compared to a net loss of $456,063 for Q1 2023.
• The company is transitioning to a new product, the Wellness Pro Infinity, and initiated an exchange program in June 2024.
• The company has a working capital deficit of $3,726,900 as of March 31, 2024, and used $158,361 in operations during the quarter, raising substantial doubt about its ability to continue as a going concern.
• The company is seeking additional funding through debt and equity placements.
• The company settled debt with some lenders, extending maturity dates and modifying terms.
• The company is in default on two matured convertible promissory notes and is in negotiations with lenders to reform the notes.
• The company borrowed $149,500 in March 2024 via an unsecured promissory note with a 12% up-front interest charge.
• The company identified material weaknesses in its internal controls over financial reporting, including the lack of an audit committee and insufficient segregation of duties.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with declining sales, increasing losses, and a significant working capital deficit. While there are some positive aspects, such as the new product launch and debt settlement, the overall sentiment is negative due to the company's financial instability and going concern uncertainty.

Positives

• The company initiated an exchange program for the new Wellness Pro Infinity in June 2024.
• The company settled debt with some lenders, extending maturity dates and modifying terms, including reversing accrued default penalties totaling $251,000.
• The company is actively seeking additional funding through debt and equity placements.
• Gross margins remain relatively stable at 75% in Q1 2024 compared to 77% in Q1 2023.

Negatives

• Net sales decreased by 23% to $290,244 in Q1 2024, compared to $378,646 in Q1 2023.
• Net loss increased to $836,274 in Q1 2024, compared to $456,063 in Q1 2023.
• The company has a working capital deficit of $3,726,900 as of March 31, 2024.
• The company used $158,361 in operations during Q1 2024.
• The company is in default on two matured convertible promissory notes.
• The company identified material weaknesses in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to accumulated net losses and a working capital deficit.
• The company's success depends on growing its revenue base and/or accessing additional sources of capital, which may not be available on commercially reasonable terms.
• The company is subject to various loss contingencies and assessments arising in the normal course of business.
• The company is in default of two matured convertible promissory notes, which could lead to further financial strain.
• The company identified material weaknesses in its internal controls over financial reporting, which could affect the reliability of its financial reporting.

Future Outlook

The company expects to obtain funding through additional debt and equity placement offerings until it consistently achieves positive cash flows from operations. The company is focused on generating cash from operations through the sale of its products and is seeking to raise additional working capital through various financing sources.

Management Comments

• Management is of the opinion that no asset is likely to be realized for an amount less than the amount at which it is recorded in the financial statements as at March 31, 2024.
• Management will continue to monitor and evaluate the designation, implementation and effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary.

Industry Context

The company operates in the bioelectronics industry, which is a developing field of electronic medicine that uses electrical impulses to alleviate pain. The company aims to offer alternatives to addictive pain-relieving drugs, such as opioids, addressing a significant public health concern.

Comparison to Industry Standards

• It is difficult to compare Electromedical Technologies directly to industry standards due to its unique product offerings and small size relative to larger medical device companies.
• Larger, more established medical device companies like Medtronic, Boston Scientific, and Abbott typically have significantly higher revenues, profits, and R&D budgets.
• Smaller companies in the bioelectronics space often focus on specific niche markets or therapeutic areas, making direct comparisons challenging.
• Given the company's financial challenges, it is crucial to monitor its ability to secure funding and successfully launch its new Wellness Pro Infinity product to remain competitive.

Legal Proceedings

• The Company is in negotiations with a lender to reform a note in default.

Related Party Transactions

• Compensation totaling $5,000 per month has been recorded for an employee as board of director fees for the three -month period ended March 31, 2024.
• Accrued salary totaling $64,154 has been recorded as of March 31, 2024 and may be converted at any time into shares of the Companys common stock at a discount of 25% of the market value on the date of conversion.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from equity offerings.
• Employees face uncertainty due to the company's going concern risk and potential for restructuring.
• Customers may be affected by the company's ability to continue operations and provide product support.
• Suppliers and creditors face risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to successfully launch the Wellness Pro Infinity product.
• The company needs to secure additional funding through debt and equity placements.
• The company needs to address the material weaknesses in its internal controls over financial reporting.
• The company needs to negotiate and reform the defaulted convertible promissory notes.

Key Dates

Keywords

Electromedical Technologies, financial results, Q1 2024, net sales, net loss, convertible notes, debt, going concern, Wellness Pro Infinity, bioelectronics, medical devices